Cart
sales@molnova.com
FPH2
CAS No. 957485-64-2
FPH2( BRD-9424 )
Catalog No. M17692 CAS No. 957485-64-2
FPH2 (BRD-9424) is a small molecule promoting differentiation of iPS-derived hepatocytes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 41 | In Stock |
|
| 5MG | 37 | In Stock |
|
| 10MG | 72 | In Stock |
|
| 25MG | 180 | In Stock |
|
| 50MG | 305 | In Stock |
|
| 100MG | 538 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFPH2
-
NoteResearch use only, not for human use.
-
Brief DescriptionFPH2 (BRD-9424) is a small molecule promoting differentiation of iPS-derived hepatocytes.
-
DescriptionFPH2 (BRD-9424) is a small molecule promoting differentiation of iPS-derived hepatocytes.
-
In VitroFPH2 induces functional proliferation of hepatocytes in vitro, and thus may be useful for expanding mature human primary hepatocytes. FPH1 and FPH2 can increase in hepatocyte nuclei count and/or elevate the number of nuclei undergoing mitosis during primary screening, and these effects on hepatocytes are concentration dependent. Cells treated with FPH1 and FPH2 also maintain their liver-specific functions. Over 7 days, FPH2 induces hepatocyte doublings at a rate that is consistent with reported liver regeneration kinetics in vivo.
-
In Vivo——
-
SynonymsBRD-9424
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number957485-64-2
-
Formula Weight353.83
-
Molecular FormulaC14H16ClN5O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 125 mg/mL; 353.28 mM
-
SMILESClc1cc(NC(=S)Nc2cn(nc2C(=O)N)CC)c(OC)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shan J, et al. Nat Chem Biol. 2013, 9(8), 514-520.
molnova catalog
related products
-
Licochalcone D
Licochalcone D may be a potential drug for human melanoma treatment by inhibiting proliferation, inducing apoptosis via the mitochondrial pathway and blocking cell migration and invasion.
-
Darizmetinib
Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
-
Emprumapimod
Emprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene.
